Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Barbara Eichhorst

Showing results (91-100 of 120) with videos related to

Pageof 12
Sort By:
Blood|June 26, 2023
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mutHenriette Huber, Eugen Tausch, Christof Schneider, et al.
The Lancet. Oncology|May 25, 2016
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trialBarbara Eichhorst, Anna-Maria Fink, Jasmin Bahlo, et al.
Hemasphere|June 17, 2026
IGLV3-21<sup>R110</sup> and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLLDeyan Y Yosifov, Sandra Robrecht, Adam Giza, et al.
Leukemia|February 12, 2020
Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study groupManuela A Hoechstetter, Raymonde Busch, Barbara Eichhorst, et al.
Leukemia|February 20, 2020
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trialCarmen D Herling, Florence Cymbalista, Carolin Groß-Ophoff-Müller, et al.
Leukemia|April 23, 2026
The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemiaCosima Drewes, Cristina López, Nnamdi Okeke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2018
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal TrialStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2022
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III TrialPeter Hillmen, Barbara Eichhorst, Jennifer R Brown, et al.
Blood|March 18, 2021
MARCKS affects cell motility and response to BTK inhibitors in CLLLaura Beckmann, Valeska Berg, Clarissa Dickhut, et al.
Blood|January 30, 2025
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trialMoritz Fürstenau, Sandra Robrecht, Christof Schneider, et al.
Pageof 12

Showing results (91-100 of 120) with videos related to

Sort By:
Pageof 12
Blood|June 26, 2023
Final analysis of the CLL2-GIVe trial: obinutuzumab, ibrutinib, and venetoclax for untreated CLL with del(17p)/TP53mutHenriette Huber, Eugen Tausch, Christof Schneider, et al.
The Lancet. Oncology|May 25, 2016
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trialBarbara Eichhorst, Anna-Maria Fink, Jasmin Bahlo, et al.
Hemasphere|June 17, 2026
IGLV3-21<sup>R110</sup> and ibrutinib treatment: Results from the double-blind, randomized, placebo-controlled GCLLSG CLL12 trial in early-stage CLLDeyan Y Yosifov, Sandra Robrecht, Adam Giza, et al.
Leukemia|February 12, 2020
Prognostic model for newly diagnosed CLL patients in Binet stage A: results of the multicenter, prospective CLL1 trial of the German CLL study groupManuela A Hoechstetter, Raymonde Busch, Barbara Eichhorst, et al.
Leukemia|February 20, 2020
Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trialCarmen D Herling, Florence Cymbalista, Carolin Groß-Ophoff-Müller, et al.
Leukemia|April 23, 2026
The spectrum of immunoglobulin heavy chain enhancer hijacking in chronic lymphocytic leukemiaCosima Drewes, Cristina López, Nnamdi Okeke, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2018
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal TrialStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2022
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III TrialPeter Hillmen, Barbara Eichhorst, Jennifer R Brown, et al.
Blood|March 18, 2021
MARCKS affects cell motility and response to BTK inhibitors in CLLLaura Beckmann, Valeska Berg, Clarissa Dickhut, et al.
Blood|January 30, 2025
MRD-guided zanubrutinib, venetoclax, and obinutuzumab in relapsed CLL: primary end point analysis from the CLL2-BZAG trialMoritz Fürstenau, Sandra Robrecht, Christof Schneider, et al.
Pageof 12